AXIM Biotechnologies, Inc. (AXIM)’s clinical trials testing a new pharmaceutical-grade cannabis chewing gum treatment option for Multiple Sclerosis (MS) pain and spasticity are drawing lots of popular and specialty media attention, with reports in Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money, Marijuana Stocks Report, Culture Magazine, and Pharmacy Choice.
A Yahoo! Finance report cited: “A recent North American Research Committee on Multiple Sclerosis (NARCOMS) survey found that the vast majority (95.1 percent) of MS sufferers are in favor of legalized medical marijuana. About 16 percent of the survey respondents reported using marijuana for their MS. More than 80 percent of MS sufferers said they would consider using marijuana if it were legal in their state.”
Medical Marijuana for Pain Relief and Management
AXIM maintains that use of legal medical cannabis can address a variety of therapeutic purposes, with pain relief and pain management typically considered a primary application for medical marijuana recommendation or card holders. Many patients anecdotally report significant improvements in the amount and intensity of pain from ongoing illnesses through use of medical marijuana.
Medical cannabis holds considerable promise as therapy for some specific, difficult-to-treat pain associated with disorders like MS and other conditions that cause nerve pain, according to research findings presented to the California Legislature. The National Institutes of Health MS Website notes that MS patients can experience “burning, tingling, and prickling (commonly called ‘pins and needles’) … sensations that happen in the absence of any stimulation. The medical term for them is dysesthesias. They are often chronic and hard to treat.”
An MSN report cites promising results in a series of trials comparing marijuana cigarettes of varying tetrahydrocannabinol (THC) strengths against traditional painkilling medications in which Igor Grant, M.D., F.R.C.P.(C), executive vice-chairman of the department of psychiatry at the University of California San Diego School of Medicine and director of the Center for Medicinal Cannabis Research at the University of California found that the marijauana pain therapy was comparable and sometimes superior to classic drugs.
A summary by Dr. Grant of research findings on the neuropsychiatirc effects of medical cannabis can be found here in pdf format.
The MSN article also references a review of 13 studies by researchers at the University of California San Francisco who noted that medical marijuana overall may provide relief for chronic neuropathic pain patients that can’t be controlled with other treatments.
However, a major obstacle to widespread general medical deployment of cannabis as a painkiller in the U.S. is the lack of standardized dose delivery, research and development of which has been severely hindered by the fact that while four U.S. states have legalized both medical and recreational marijuana use, and a total of 23 states, the District of Columbia and Guam now allow for comprehensive public medical marijuana and cannabis programs, cannabis remains a Schedule I substance under the Controlled Substances Act, the most tightly restricted category reserved for drugs deemed by the feds to have “no currently accepted medical use.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?